Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results
Author:
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology
Link
http://www.nature.com/articles/6702936.pdf
Reference9 articles.
1. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113: 2002.e1–2002.e12.
2. Fung AE, Rosenfeld PJ, Reichel E . The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344–1349.
3. Benson SE, Schlottmann PG, Bunce C, Xing W, Charteris DG . Assessment of the reproducibility and repeatability of a method of grading macular subretinal fluid using optical coherence tomography. Eye 2006; 20: 1030–1033.
4. Casswell AG, Kohen D, Bird AC . Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985; 69: 397–403.
5. Talks SJ, Setty R, Clarke L . The incidence and outcome of photodynamic therapy for macular degeneration in the Northern region of the UK. Eye 2004; 18: 588–594.
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario;Indian Journal of Ophthalmology;2017
2. Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration;Current Opinion in Ophthalmology;2016-05
3. Predictors of visual and anatomical outcomes for neovascular age-related macular degeneration treated with bevacizumab;Biomedical Reports;2015-04-16
4. The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review;BMJ Open;2014-07-17
5. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis;Clinical Interventions in Aging;2014-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3